Empyrean Capital Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Empyrean Capital Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-977,700	Closed	-$675K	–	214
2020 Q4	$675K	Hold	977,700	–	–	0.02%	118
2020 Q3	$2.2M	Sell	977,700 -22,300	-2%	-$63.7K	0.09%	75
2020 Q2	$3.58M	Sell	1,000,000 -286,200	-22%	-$1.03M	0.21%	56
2020 Q1	$4.89M	Sell	1,286,200 -850,000	-40%	-$2.8M	0.34%	42
2019 Q4	$6.43M	Buy	+2,136,200	New	+$5.55M	0.42%	34

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Empyrean Capital Partners's BMY.RT Position: Q1 2021 in Review

Empyrean Capital Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 977,700 shares — an estimated $675K sold.

Empyrean Capital Partners first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $6.43M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Empyrean Capital Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Empyrean Capital Partners sold 977,700 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $675K.
Empyrean Capital Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Empyrean Capital Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $6.43M in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Empyrean Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.